Elanco Animal Health (NYSE:ELAN) Shares Down 4.5% – What’s Next?

Elanco Animal Health Incorporated (NYSE:ELAN)’s share price dropped 4.5% on Tuesday . The company traded as low as $20.68 and last traded at $20.7090. Approximately 4,921,180 shares were traded during trading, a decline of 16% from the average daily volume of 5,833,618 shares. The stock had previously closed at $21.69.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ELAN shares. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. UBS Group boosted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday. Finally, Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.78.

Elanco Animal Health Price Performance

The stock has a market cap of $10.56 billion, a price-to-earnings ratio of 354.39, a PEG ratio of 2.89 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The company’s 50 day moving average is $21.72 and its 200 day moving average is $17.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaQuest LLC increased its position in shares of Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after acquiring an additional 718 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after purchasing an additional 798 shares in the last quarter. MTM Investment Management LLC raised its position in Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock valued at $218,000 after purchasing an additional 800 shares during the period. HighTower Advisors LLC raised its position in Elanco Animal Health by 7.0% in the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock valued at $131,000 after purchasing an additional 810 shares during the period. Finally, US Bancorp DE lifted its stake in shares of Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after purchasing an additional 824 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.